Kura Oncology (KURA) is a San Diego-based commercial-stage biopharmaceutical company focused on precision oncology. Its lead product, KOMZIFTI (ziftomenib), is an approved once-daily oral menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia, and the company is developing darlifarnib, a farnesyl transferase inhibitor, in HRAS-mutant salivary gland cancer.
Shares traded at $7.55 on Tuesday morning, up $0.46 or 6.49%, against Monday's close of $7.09. The direction was clearly positive, and the advance recovered roughly two-thirds of the prior session's loss. The immediate driver cited by markets was the disclosure of a sizable open-market purchase by the company's chief executive, filed after Monday's close.
A Form 4 filed Monday evening showed President and CEO Troy Wilson bought 200,000 shares across two sessions — 98,881 shares on Nov. 13 at a weighted average of $7.63 and 101,119 shares on Nov. 16 at a weighted average of $7.42 — for a combined $1.5 million. The purchases were made in the open market, not through option exercises or pre-arranged award vesting, and raised his direct stake by about 46% to 635,456 shares.
The signal mattered because of where it landed. Monday's close of $7.09 sat within 5% of the 52-week low of $6.75, and the stock is down roughly 32% year to date. When a chief executive commits personal capital at the bottom of a drawdown, investors often read it as the strongest available statement that management sees the selloff as disconnected from the underlying business.
The bounce also reflects mechanics as much as news. KURA fell from $10.21 to $7.61 on Nov. 4 in a single session on more than 8 million shares, then slid another 10.6% the following day to $6.80. That two-day rout of roughly 31% left the stock heavily oversold, and Monday's additional 8.75% drop cleared out remaining momentum sellers.
Fundamentally, the third quarter delivered KOMZIFTI net product revenue of $13.9 million, up 53% sequentially, with new patient starts up 30% and total prescriptions up 65%. Total revenue of $22.83 million missed consensus, and collaboration revenue from Kyowa Kirin fell year over year, which amplified the negative reaction. No new operating disclosure arrived Tuesday.
Management is presenting at the UBS Global Biopharma Conference on Tuesday and the Jefferies Global Healthcare Conference on Wednesday. With the ASH annual meeting approaching — eight ziftomenib abstracts, including first clinical data combining ziftomenib with FLT3 inhibitors — the calendar gives investors fresh reasons to re-engage. No analyst rating change was issued Tuesday.
Turnover in the first hours of trading was active but had not approached the 8.2 million shares that changed hands on Nov. 4, when volume ran roughly four times the three-month average of about 2.1 million shares. Broader small-cap biotechnology indices traded narrowly mixed, and the move did not appear to be a sector-wide risk-on rotation. Instead, KURA moved as an outlier on its own filing.
Technically, the stock is attempting to hold above the Nov. 5 low of $6.75 while remaining well below its 50-day moving average and far from the August high of $13.59. A close above $7.73 would reclaim Monday's opening level; failure to hold $7.00 would put the 52-week low back in play.
The score runs from 0 — no meaningful news and a move that is entirely normal for the stock — to 100, reserved for transformative news driving an extreme, rare price move. This event scores 20 out of 100.
The verified news was a $1.5 million open-market insider purchase, a genuine confidence signal but not an operating catalyst, so the catalyst component is modest relative to the company's roughly $670 million market value. The price move was roughly twice the stock's typical daily swing of about 3.2%, and ten sessions in the past 69 produced equal or larger moves, including drops of 23% and gains of 10.6%. That combination of moderate news and a fairly ordinary swing for this name keeps the score low.
Attention now turns to the ASH data, where FLT3 combination results and longer-term frontline durability updates will be weighed against competing menin inhibitor programs. Management's conference appearances this week may add color on KOMZIFTI launch momentum, including prescribing account growth and repeat prescriptions. Investors will also watch for clarity on darlifarnib's registrational timeline, with an IND planned by year-end and study initiation targeted for the first half of 2027.
Risks remain substantial. The company reported a $70.2 million quarterly net loss, and competition from additional menin inhibitor entrants could pressure share even as the market expands. Continued insider buying would reinforce the floor narrative; renewed selling pressure below $7 would suggest the rebound was a technical bounce rather than a change in trend.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ by strategy logic, holding timeframe, performance metrics and the symbols they trade, and only those performing best under current market conditions appear in this section. For traders interested in systematic execution rather than discretionary calls, it is a practical starting point for reviewing live bot performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for KURA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.586). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of biopharmaceutical services
Industry Biotechnology